デフォルト表紙
市場調査レポート
商品コード
1319063

がん領域バイオシミラー市場:用途別(がん治療薬、支持療法薬)、エンドユーザー別(病院、小売薬局)-世界予測2023-2030年

Oncology Biosimilars Market by Application (Cancer Treatment Drugs, Supportive Care Drugs), End-User (Hospitals, Retail Pharmacies) - Cumulative Impact of COVID-19, Russia Ukraine Conflict, and High Inflation - Global Forecast 2023-2030

出版日: | 発行: 360iResearch | ページ情報: 英文 185 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=152.52円
がん領域バイオシミラー市場:用途別(がん治療薬、支持療法薬)、エンドユーザー別(病院、小売薬局)-世界予測2023-2030年
出版日: 2023年06月12日
発行: 360iResearch
ページ情報: 英文 185 Pages
納期: 即日から翌営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

がん領域バイオシミラーの世界市場は、2023年に46億5,176万米ドル、CAGR18.09%で大きく成長し、2030年には149億1,629万米ドルに達すると予測されています。

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスは世界のがん領域バイオシミラー市場を評価するために不可欠です。ビジネス戦略と製品満足度の主要指標を検証することで、ベンダーの包括的な評価を提供し、ユーザーが特定のニーズに基づいて情報に基づいた意思決定を行えるようにします。この高度な分析により、ベンダーは成功の度合いが異なる4つの象限に整理されます:フォアフロント(F)、パスファインダー(P)、ニッチ(N)、バイタル(V)です。

市場シェア分析

市場シェア分析では、特定の市場領域におけるベンダーの現状を洞察することができます。全体的な収益、顧客基盤、その他の主要指標に対するベンダーの貢献度を比較することで、企業が市場シェアを争う際に、自社の業績や直面している状況をより深く理解することができます。また、本分析では、調査した基準年において、特定のセクターがどの程度競合しているのか、蓄積、断片化の優位性、合併の特徴についても明らかにしています。

本レポートは、以下のポイントに関する洞察を提供します:

1.市場の浸透度:主要企業が提供する市場に関する包括的な情報を提供します。

2.市場の発展:有利な新興市場に関する詳細情報を提供し、市場の成熟セグメントにおける浸透度を分析します。

3.市場の多様化:新製品の上市、未開発地域、最近の開発、投資に関する詳細情報を提供します。

4.市場の動向:COVID-19、ロシア・ウクライナ紛争、高インフレの累積的な影響を包括的に理解することができます。

5.競合の評価と情報:主要企業の市場シェア、戦略、製品、認証、規制状況、特許状況、製造能力を網羅的に評価します。

6.製品開発およびイノベーション:将来技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような質問にお答えします:

1.がん領域バイオシミラーの世界市場規模および予測は?

2.予測期間中、世界のがん領域バイオシミラー市場を形成するCOVID-19の阻害要因と影響は?

3.がん領域バイオシミラーの世界市場において予測期間中に投資すべき製品/セグメント/アプリケーション/分野は?

4.がん領域バイオシミラーの世界市場における競争戦略は?

5.がん領域バイオシミラーの世界市場における技術動向と規制の枠組みは?

6.がん領域バイオシミラーの世界市場における主要ベンダーの市場シェアは?

7.がん領域バイオシミラーの世界市場への参入には、どのような形態や戦略的な動きが適していると考えられるか?

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

  • 市場力学
    • 促進要因
      • 規制当局による製品の商業化の迅速な承認
      • さまざまな種類のがんや白血病の発生率の増加
      • 臨床医薬品開発における最近の革新
    • 抑制要因
      • 調査には高額な費用がかかる
    • 機会
      • 新しく革新的な治療オプションのイントロダクション
      • 戦略的提携と生産能力拡大のための投資
    • 課題
      • 限られた臨床安全性と有効性データ
  • 市場動向
  • COVID-19の累積的な影響
  • ロシア・ウクライナ紛争の累積的影響
  • 高インフレの累積的影響
  • ポーターのファイブフォース分析
  • バリューチェーンとクリティカルパス分析
  • 規制の枠組み
  • 顧客のカスタマイズ

第6章 がん領域バイオシミラー市場:用途別

  • がん治療薬
  • 支持療法薬

第7章 がん領域バイオシミラー市場:エンドユーザー別

  • 病院
  • 小売薬局

第8章 南北アメリカのがん領域バイオシミラー市場

  • アルゼンチン
  • ブラジル
  • カナダ
  • メキシコ
  • 米国

第9章 アジア太平洋地域のがん領域バイオシミラー市場

  • オーストラリア
  • 中国
  • インド
  • インドネシア
  • 日本
  • マレーシア
  • フィリピン
  • シンガポール
  • 韓国
  • 台湾
  • タイ
  • ベトナム

第10章 欧州・中東・アフリカのがん領域バイオシミラー市場

  • デンマーク
  • エジプト
  • フィンランド
  • フランス
  • ドイツ
  • イスラエル
  • イタリア
  • オランダ
  • ナイジェリア
  • ノルウェー
  • ポーランド
  • カタール
  • ロシア
  • サウジアラビア
  • 南アフリカ
  • スペイン
  • スウェーデン
  • スイス
  • トルコ
  • アラブ首長国連邦
  • 英国

第11章 競合情勢

  • FPNVポジショニングマトリクス
  • 市場シェア分析:主要企業別
  • 競合シナリオ分析:主要企業別

第12章 掲載企業一覧

第13章 付録

  • ディスカッションガイド
  • ライセンスと価格について
図表

LIST OF FIGURES

  • FIGURE 1. ONCOLOGY BIOSIMILARS MARKET RESEARCH PROCESS
  • FIGURE 2. ONCOLOGY BIOSIMILARS MARKET SIZE, 2022 VS 2030
  • FIGURE 3. ONCOLOGY BIOSIMILARS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2022 VS 2030 (%)
  • FIGURE 5. ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2022 VS 2030 (%)
  • FIGURE 6. ONCOLOGY BIOSIMILARS MARKET SIZE, BY REGION, 2022 VS 2030 (%)
  • FIGURE 7. ONCOLOGY BIOSIMILARS MARKET DYNAMICS
  • FIGURE 8. ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 9. ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS ONCOLOGY BIOSIMILARS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 11. UNITED STATES ONCOLOGY BIOSIMILARS MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 12. ASIA-PACIFIC ONCOLOGY BIOSIMILARS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 13. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY BIOSIMILARS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 14. ONCOLOGY BIOSIMILARS MARKET, FPNV POSITIONING MATRIX, 2022
  • FIGURE 15. ONCOLOGY BIOSIMILARS MARKET SHARE, BY KEY PLAYER, 2022

LIST OF TABLES

  • TABLE 1. ONCOLOGY BIOSIMILARS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
  • TABLE 3. ONCOLOGY BIOSIMILARS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 5. ONCOLOGY BIOSIMILARS MARKET SIZE, BY CANCER TREATMENT DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 6. ONCOLOGY BIOSIMILARS MARKET SIZE, BY SUPPORTIVE CARE DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 8. ONCOLOGY BIOSIMILARS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. ONCOLOGY BIOSIMILARS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. AMERICAS ONCOLOGY BIOSIMILARS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 11. AMERICAS ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 12. AMERICAS ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 13. ARGENTINA ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 14. ARGENTINA ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 15. BRAZIL ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 16. BRAZIL ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 17. CANADA ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 18. CANADA ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 19. MEXICO ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 20. MEXICO ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 21. UNITED STATES ONCOLOGY BIOSIMILARS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 22. UNITED STATES ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 23. UNITED STATES ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 24. ASIA-PACIFIC ONCOLOGY BIOSIMILARS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 25. ASIA-PACIFIC ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 26. ASIA-PACIFIC ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 27. AUSTRALIA ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 28. AUSTRALIA ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 29. CHINA ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 30. CHINA ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 31. INDIA ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 32. INDIA ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 33. INDONESIA ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 34. INDONESIA ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 35. JAPAN ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 36. JAPAN ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 37. MALAYSIA ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 38. MALAYSIA ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 39. PHILIPPINES ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 40. PHILIPPINES ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 41. SINGAPORE ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 42. SINGAPORE ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 43. SOUTH KOREA ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 44. SOUTH KOREA ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 45. TAIWAN ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 46. TAIWAN ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 47. THAILAND ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 48. THAILAND ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 49. VIETNAM ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 50. VIETNAM ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 51. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY BIOSIMILARS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 52. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 53. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 54. DENMARK ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 55. DENMARK ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 56. EGYPT ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 57. EGYPT ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 58. FINLAND ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 59. FINLAND ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 60. FRANCE ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 61. FRANCE ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 62. GERMANY ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 63. GERMANY ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 64. ISRAEL ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 65. ISRAEL ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 66. ITALY ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 67. ITALY ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 68. NETHERLANDS ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 69. NETHERLANDS ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 70. NIGERIA ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 71. NIGERIA ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 72. NORWAY ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 73. NORWAY ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 74. POLAND ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 75. POLAND ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 76. QATAR ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 77. QATAR ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 78. RUSSIA ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 79. RUSSIA ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 80. SAUDI ARABIA ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 81. SAUDI ARABIA ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 82. SOUTH AFRICA ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 83. SOUTH AFRICA ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 84. SPAIN ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 85. SPAIN ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 86. SWEDEN ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 87. SWEDEN ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 88. SWITZERLAND ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 89. SWITZERLAND ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 90. TURKEY ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 91. TURKEY ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 92. UNITED ARAB EMIRATES ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 93. UNITED ARAB EMIRATES ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 94. UNITED KINGDOM ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 95. UNITED KINGDOM ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 96. ONCOLOGY BIOSIMILARS MARKET, FPNV POSITIONING MATRIX, 2022
  • TABLE 97. ONCOLOGY BIOSIMILARS MARKET SHARE, BY KEY PLAYER, 2022
  • TABLE 98. ONCOLOGY BIOSIMILARS MARKET LICENSE & PRICING
目次
Product Code: MRR-036C5CF3A8CD

The Global Oncology Biosimilars Market is forecasted to grow significantly, with a projected USD 4,651.76 million in 2023 at a CAGR of 18.09% and expected to reach a staggering USD 14,916.29 million by 2030.

The Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and High Inflation is expected to have significant long-term effects on the Global Oncology Biosimilars Market. The ongoing research considers the changes in consumer behavior, supply chain disruptions, and government interventions caused by the pandemic. Similarly, the report considers the ongoing political and economic uncertainty in Eastern Europe caused by the Russia-Ukraine Conflict and its potential implications for demand-supply balances, pressure on pricing variants, and import/export and trading. Additionally, the report addresses the impact of High Inflation on the global economy and details fiscal policies measuring and reducing its effects on demand, supply, cash flow, and currency exchange.

Market Segmentation & Coverage:

This research report categorizes the Global Oncology Biosimilars Market in order to forecast the revenues and analyze trends in each of following sub-markets:

Based on Application, market is studied across Cancer Treatment Drugs and Supportive Care Drugs. The Cancer Treatment Drugs is projected to witness significant market share during forecast period.

Based on End-User, market is studied across Hospitals and Retail Pharmacies. The Hospitals is projected to witness significant market share during forecast period.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Americas commanded largest market share of 38.75% in 2022, followed by Europe, Middle East & Africa.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is essential for assessing the Global Oncology Biosimilars Market. It provides a comprehensive evaluation of vendors by examining key metrics within Business Strategy and Product Satisfaction, allowing users to make informed decisions based on their specific needs. This advanced analysis then organizes these vendors into four distinct quadrants, which represent varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital(V).

Market Share Analysis:

The Market Share Analysis offers an insightful look at the current state of vendors in a particular market space. By comparing vendor contributions to overall revenue, customer base, and other key metrics, we can give companies a greater understanding of their performance and what they are up against when competing for market share. The analysis also sheds light on just how competitive any given sector is about accumulation, fragmentation dominance, and amalgamation traits over the base year period studied.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players

2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets

3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments

4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation

5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players

6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Oncology Biosimilars Market?

2. What are the inhibiting factors and impact of COVID-19 shaping the Global Oncology Biosimilars Market during the forecast period?

3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Oncology Biosimilars Market?

4. What is the competitive strategic window for opportunities in the Global Oncology Biosimilars Market?

5. What are the technology trends and regulatory frameworks in the Global Oncology Biosimilars Market?

6. What is the market share of the leading vendors in the Global Oncology Biosimilars Market?

7. What modes and strategic moves are considered suitable for entering the Global Oncology Biosimilars Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Oncology Biosimilars Market, by Application, 2022 vs 2030
  • 4.3. Oncology Biosimilars Market, by End-User, 2022 vs 2030
  • 4.4. Oncology Biosimilars Market, by Region, 2022 vs 2030

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rapid approval by regulatory authorities for commercialization of products
      • 5.1.1.2. Rising incidence of various types of cancers and leukemia
      • 5.1.1.3. Recent innovation in clinical drug development
    • 5.1.2. Restraints
      • 5.1.2.1. High costs involved in the research
    • 5.1.3. Opportunities
      • 5.1.3.1. Introduction of new and innovative treatment options
      • 5.1.3.2. Strategic alliances and investment for capacity expansion
    • 5.1.4. Challenges
      • 5.1.4.1. Limited clinical safety and efficacy data
  • 5.2. Market Trends
  • 5.3. Cumulative Impact of COVID-19
  • 5.4. Cumulative Impact of Russia-Ukraine Conflict
  • 5.5. Cumulative Impact of High Inflation
  • 5.6. Porter's Five Forces Analysis
    • 5.6.1. Threat of New Entrants
    • 5.6.2. Threat of Substitutes
    • 5.6.3. Bargaining Power of Customers
    • 5.6.4. Bargaining Power of Suppliers
    • 5.6.5. Industry Rivalry
  • 5.7. Value Chain & Critical Path Analysis
  • 5.8. Regulatory Framework
  • 5.9. Client Customization

6. Oncology Biosimilars Market, by Application

  • 6.1. Introduction
  • 6.2. Cancer Treatment Drugs
  • 6.3. Supportive Care Drugs

7. Oncology Biosimilars Market, by End-User

  • 7.1. Introduction
  • 7.2. Hospitals
  • 7.3. Retail Pharmacies

8. Americas Oncology Biosimilars Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Oncology Biosimilars Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Oncology Biosimilars Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. FPNV Positioning Matrix
  • 11.2. Market Share Analysis, By Key Player
  • 11.3. Competitive Scenario Analysis, By Key Player

12. List of Company Mentioned

13. Appendix

  • 13.1. Discussion Guide
  • 13.2. License & Pricing